Concepedia

Publication | Open Access

A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1

DOIFull Paper Access

20

Citations

31

References

2018

Year

Frede Donskov, Niels Viggo Jensen, Torben Smidt-Hansen, Line Brøndum, Poul Geertsen
Acta Oncologica

Abstract

The addition of BEV to IL-2/IFN did not add efficacy in mRCC. (ClinicalTrials.gov, NCT01274273.).

References

YearCitations

Page 1